3/25
04:32 pm
nmra
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
3/19
07:27 pm
nmra
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
3/16
07:00 am
nmra
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
High
Report
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
3/9
08:22 pm
nmra
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity [Yahoo! Finance]
Low
Report
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity [Yahoo! Finance]
3/4
05:57 am
nmra
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]
Neutral
Report
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]
2/17
07:23 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/4
07:00 am
nmra
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
1/13
05:44 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
1/12
08:04 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
1/5
01:08 pm
nmra
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
1/5
06:53 am
nmra
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
High
Report
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
1/5
06:35 am
nmra
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]
High
Report
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]
1/5
06:35 am
nmra
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
High
Report
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
1/5
06:30 am
nmra
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
Medium
Report
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
1/3
06:28 am
nmra
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) [Yahoo! Finance]
Low
Report
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) [Yahoo! Finance]